Abstract 1541
Background
Metastatic Leydig cells tumours (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed LDLR-TERT gene fusion upon routine genetic profiling for detection of therapeutic targets, which was then followed by an investigation into a cohort of additional LCT.
Methods
20 LCT (7 metastatic and 13 primary tumours) from 3 participating institutions (Caris Life Sciences, Phoenix, USA; Clinical Hospital Center, Zagreb, Croatia and Biopticka Laborator, Plzen, Czech Republic) were analyzed using massively parallel DNA and RNA sequencing (NGS) approach. Immunohistochemistry (IHC) was used for detection of selected protein biomarkers.
Results
TERT gene fusions were detected only in metastatic Leydig cell tumours, in three of 5 successfully analyzed cases (RMST:TERT, LDLR:TERT and B4GALT5:TERT, respectively). The case with B4GALT5:TERT fusion also showed amplifications (>6 copies) of TOP1 and CCND3 genes. TP53 mutation (M246I) was detected in one metastatic tumour without TERT fusion. No gene fusions were found in any primary tumours (0/8 successfully analyzed). 3/6 primary tumours showed multiple gene amplifications, without a consistent pattern. At the protein level (IHC) 5/7 metastatic and 6/7 primary tumours over-expressed TOP1. Full length androgen receptor (AR) was overexpressed in 7/8 primary tumours (without detectable ARv7 mRNA or ARv7 protein), but only in 1 of 5 metastatic LCT. No tumours exhibited high tumour mutational burden, microsatellite instability nor expressed PD-L1 in tumour cells.
Conclusions
Our study for the first time identified TERT gene fusions as a main/sole detected genetic alteration and a potential therapeutic target in malignant, metastatic Leydig cell tumours. Additional biomarkers (TOP1 amplification and over-expression) may help guide decisions on chemotherapy for selected individual patients. Androgen receptor blockade may be considered in AR overexpressing tumours without evidence of ARv7 presence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Caris Life Sciences.
Funding
Caris Life Sciences.
Disclosure
Z. Gatalica: Leadership role: Caris Life Sciences. J. Xiu: Leadership role, employment: Caris Life Sciences. J. Swensen: Leadership role, employment: Caris Life Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
3988 - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.
Presenter: Sara Santagata
Session: Poster Display session 3
Resources:
Abstract
2142 - Low NK Cell Abundance Correlates with High Expression of PD-1 in CD8+ T Cells
Presenter: Moon Hee Lee
Session: Poster Display session 3
Resources:
Abstract
5501 - Tobacco smoking is associated with the immune suppressive microenvironment in head and neck squamous cell carcinoma (HNSCC)
Presenter: Christine Chung
Session: Poster Display session 3
Resources:
Abstract
5726 - Evaluation of Antibody-Dependent Cell Cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy.
Presenter: Francesca Sparano
Session: Poster Display session 3
Resources:
Abstract
2534 - Radiomic Signatures for Identification of Tumors Sensitive to Nivolumab or Docetaxel in Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Presenter: Laurent Dercle
Session: Poster Display session 3
Resources:
Abstract
3366 - Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers
Presenter: FEIYU ZHANG
Session: Poster Display session 3
Resources:
Abstract
2089 - Pathogenesis of Myocarditis Following Treatment with Immune Checkpoint Inhibitors in a Cynomolgus Monkey Model
Presenter: Changhua Ji
Session: Poster Display session 3
Resources:
Abstract
4463 - Effects of dietary restriction in cancer patients receiving irinotecan
Presenter: Ruben Van Eerden
Session: Poster Display session 3
Resources:
Abstract
4841 - Investigating the Link between Burn Injury and Tumorigenesis
Presenter: Lucy Barrett
Session: Poster Display session 3
Resources:
Abstract
4619 - Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients
Presenter: Joanna Huszno
Session: Poster Display session 3
Resources:
Abstract